TTP, HUS, DIC, HELLP and HIT: low platelets that clot
- Look-alikes compared
Five dangerous conditions all lower the platelets while making clots. Each has a different first move, and the wrong one can kill.
What it is
In these conditions platelets are low because they are being used up in clots, not because the marrow fails. TTP, HUS and HELLP are thrombotic microangiopathies: platelet-rich clots in small vessels shred red cells (schistocytes) and damage organs. DIC is consumption of both platelets and clotting factors, so the clotting times lengthen. HIT is an antibody that activates platelets after heparin exposure; it causes large-vessel clots, usually without schistocytes.
The difference in one line
- TTP: very low ADAMTS13 activity (usually an autoantibody) leaves ultra-large VWF strings that trap platelets; confusion and other brain signs are common, kidney injury usually mild.
- HUS: kidney injury leads; typical HUS follows Shiga toxin-producing E. coli diarrhoea, mostly in children; atypical HUS comes from uncontrolled complement.
- DIC: a trigger (sepsis, trauma, obstetric catastrophe, acute promyelocytic leukaemia) with low platelets, long PT and aPTT, low fibrinogen and high D-dimer.
- HELLP: haemolysis, raised liver enzymes and low platelets in late pregnancy or just after delivery, often with pre-eclampsia.
- HIT: platelets fall by more than half about 5–10 days after heparin starts (sooner with recent exposure), with venous or arterial clots; platelets rarely fall very low.
Five that clot, side by side
| Condition | Setting | Schistocytes | PT, aPTT, fibrinogen | Organ hit hardest | First move |
|---|---|---|---|---|---|
| TTP | Adults, often women; no obvious trigger | Yes, many | Normal | Brain (kidney mild) | Urgent plasma exchange after an ADAMTS13 sample; immunosuppression |
| HUS | Child after bloody diarrhoea (typical) or complement defect (atypical) | Yes | Normal | Kidney | Supportive care and dialysis; complement inhibitor in atypical HUS |
| DIC | Sepsis, trauma, obstetric event, APL | Sometimes, few | Long, long, low | Many; bleeding and clotting | Treat the cause; replace components if bleeding |
| HELLP | Late pregnancy or postpartum, hypertension | Yes | Usually normal (long if DIC develops) | Liver | Stabilise and deliver |
| HIT | Heparin 5–10 days earlier | No | Normal | Veins and arteries (large clots) | Stop all heparin; start a non-heparin anticoagulant |
In clinical practice
- Untreated TTP is usually fatal and treated TTP mostly survives, so plasma exchange starts on suspicion, not after the ADAMTS13 result returns.
- Platelet transfusion is avoided in TTP and HIT unless bleeding is life-threatening, because it can feed new clots.
- In HIT, warfarin is not started until the platelets recover: early warfarin can cause venous limb gangrene.
- In typical HUS, antibiotics and antimotility drugs are generally avoided because they may increase toxin release or exposure.
- HELLP can be confused with acute fatty liver of pregnancy; low glucose and long clotting times favour fatty liver.
How it is confirmed
- Every patient with low platelets and anaemia: smear for schistocytes, LDH, bilirubin, haptoglobin, reticulocytes, DAT, creatinine, PT, aPTT and fibrinogen.
- Schistocytes with normal clotting times: send ADAMTS13 before plasma and call haematology the same day; a clinical score (such as PLASMIC) helps while waiting.
- Suspected HIT: score the clinical probability (the 4Ts), then anti-PF4/heparin antibodies; a functional assay confirms a positive result.
- Diarrhoea with kidney injury: stool testing for Shiga toxin-producing E. coli; no toxin and low complement or a recurrence suggests atypical HUS.
- Pregnancy: blood pressure, urine protein, liver enzymes and platelets together; involve obstetrics at once.
Common traps
- Waiting for all five classic TTP features (fever, confusion, kidney injury, anaemia, low platelets): most patients do not have them all.
- Calling HIT a microangiopathy: it causes large-vessel clots, and the smear usually shows no schistocytes.
- Treating HIT by merely switching to low-molecular-weight heparin: it cross-reacts; all heparin must stop.
- Reading normal clotting times as 'not DIC, so not serious': TTP, HUS and HELLP all have normal clotting times and are emergencies.
Test yourself
Think of the answer, then tap the question to see it.
Which single finding separates DIC from TTP in a patient with schistocytes and low platelets?
The clotting tests: DIC uses up clotting factors, so PT and aPTT lengthen and fibrinogen falls; in TTP they are normal.
Why is plasma exchange started in suspected TTP before the ADAMTS13 result is back?
Untreated TTP kills quickly; exchange removes the antibody and supplies ADAMTS13, so delay costs more than an unnecessary exchange.
Eight days after hip surgery on heparin, platelets fall by 60% and a DVT appears. Why is switching to low-molecular-weight heparin wrong?
This is HIT, and the antibody cross-reacts with low-molecular-weight heparin; all heparin stops and a non-heparin anticoagulant starts.
A four-year-old has bloody diarrhoea, then pallor, low platelets and rising creatinine. What is the diagnosis, and what is the mainstay of treatment?
Typical (Shiga toxin) HUS; supportive care with fluids, transfusion when needed and dialysis for severe kidney injury.
Elsewhere in DurgiPedia
- Thrombotic microangiopathies: TTP vs HUS
- Thrombotic microangiopathy: the kidney
- Immune thrombocytopenias: ITP and HIT
- Disseminated intravascular coagulation: how consumption causes both clots and bleeding
- Bleeding and clotting emergencies in the ICU (DIC, low platelets, HIT) and tumour lysis: what nurses watch
Connections
In Pharmacology4
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Thrombotic Thrombocytopenic Purpura (TTP) (National Heart, Lung, and Blood Institute (NHLBI), 2024); Hemolytic-uremic syndrome (MedlinePlus, U.S. National Library of Medicine, 2024); HELLP syndrome (MedlinePlus (U.S. National Library of Medicine), 2024); Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management (Journal of Clinical Medicine, 2021).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
